Skip to Main Content
Skip Nav Destination

Online First / Early View

Online first articles are accepted and edited, peer reviewed articles that are not yet assigned to volumes/issues, but are citable using DOI.

Online First

Review Articles May 10 2025
The Concept of “Converse Therapeutic Hierarchy” for Patients with Hepatocellular Carcinoma
Liver Cancer (2025) https://doi.org/10.1159/000546360
Research Articles April 29 2025
Predicting Survival Outcomes in Patients with Hepatocellular Carcinoma Receiving Lenvatinib by Using the Up7-ALBI Score
Liver Cancer (2025) https://doi.org/10.1159/000546185
Review Articles April 29 2025
Current Perspectives on Perioperative Combination Therapy for Hepatocellular Carcinoma
Liver Cancer (2025) https://doi.org/10.1159/000546138
Research Articles April 23 2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study
Liver Cancer (2025) https://doi.org/10.1159/000546052
Research Articles April 22 2025
Comparison of Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging and Contrast-Enhanced Computed Tomography for the Noninvasive Diagnosis of Hepatocellular Carcinoma
Liver Cancer (2025) https://doi.org/10.1159/000545965
Research Articles April 22 2025
Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma
Liver Cancer (2025) https://doi.org/10.1159/000545891
Research Articles April 4 2025
Detection of Circulating mRNA Variants in Hepatocellular Carcinoma Patients Using Targeted RNAseq
Liver Cancer (2025) https://doi.org/10.1159/000545366
Research Articles April 3 2025
Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study
Liver Cancer (2025) https://doi.org/10.1159/000545545
Research Articles March 26 2025
Current Surveillance Strategy Is Less Effective for Detecting Early-Stage Hepatocellular Carcinoma in Patients with Non-Viral and Non-Cirrhotic Liver Disease
Liver Cancer (2025) https://doi.org/10.1159/000542805
Research Articles March 5 2025
18F-FDG PET/CT Predicts the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation
Liver Cancer (2025) https://doi.org/10.1159/000544966
Research Articles March 3 2025
Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150
Liver Cancer (2025) https://doi.org/10.1159/000544981
Guidelines March 3 2025
Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma
Liver Cancer (2025) https://doi.org/10.1159/000544976
Letters March 3 2025
Reevaluating the Role of Demographic and Etiological Factors in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
Liver Cancer (2025) https://doi.org/10.1159/000544964
Case Reports February 20 2025
Autologous Tumor-Infiltrating Lymphocyte Infusion plus Anti-Programmed Cell Death Protein 1 Therapy to Cure Advanced Hepatocellular Carcinoma following Palliative Hepatectomy
Liver Cancer (2025) https://doi.org/10.1159/000544163
Research Articles February 13 2025
Conversion Surgery after Immune Checkpoint Inhibitor-Based Combination Therapy for Initially Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study
Liver Cancer (2025) https://doi.org/10.1159/000543994
Research Articles January 22 2025
Non-Invasive Kupffer-CEUS Enhances the Accuracy of Focal Liver Lesions Diagnosis in Patients with Liver Cirrhosis or Fibrosis: A Prospective Multicenter Study from China
Liver Cancer (2025) https://doi.org/10.1159/000543501
Research Articles January 21 2025
Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy
Liver Cancer (2025) https://doi.org/10.1159/000543602
Research Articles January 21 2025
Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab
Liver Cancer (2025) https://doi.org/10.1159/000543666
Research Articles December 28 2024
High Frequency of CTNNB1 Variants Associated with Benign and Malignant Liver Tumors in Patients with Congenital Porto-Systemic Shunts
Liver Cancer (2024) https://doi.org/10.1159/000543217
Research Articles December 18 2024
Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study
Liver Cancer (2024) https://doi.org/10.1159/000542285
Letters December 10 2024
Combination Assay of Methylated HOXA1 with Tumor Markers for Detection of Early-Stage Hepatocellular Carcinoma
Liver Cancer (2024) https://doi.org/10.1159/000543002
Research Articles December 4 2024
Treatment Duration of Adjuvant Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Patients at High Risk of Recurrence after Resection: A Prospective, Multicentric Cohort Study
Liver Cancer (2024) https://doi.org/10.1159/000542954
Review Articles November 21 2024
Immunometabolic Targets in CD8+ T Cells within the Tumor Microenvironment of Hepatocellular Carcinoma
Liver Cancer (2024) https://doi.org/10.1159/000542578
Research Articles November 14 2024
First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial
Liver Cancer (2024) https://doi.org/10.1159/000542572

Early View

Research Articles June 19 2025
Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study
Liver Cancer (2025) https://doi.org/10.1159/000546899
Guidelines June 19 2025
Consensus Guideline of Ablation for Metastatic Liver Tumors by Taiwan Academy of Tumor Ablation
Liver Cancer (2025) https://doi.org/10.1159/000546765
Research Articles June 14 2025
Fever Following Treatment with Atezolizumab Plus Bevacizumab Predicts Liver Injury in Patients with Unresectable Hepatocellular Carcinoma: A Prospective Observational Analysis
Liver Cancer (2025) https://doi.org/10.1159/000546967
Review Articles June 12 2025
The evolving role of imaging in hepatocellular carcinoma: from pathomolecular profiling to prognostic decision-making
Liver Cancer (2025) https://doi.org/10.1159/000546966
Systematic Review June 12 2025
Updated Network Meta-Analysis of First-Line Systemic Treatments for Advanced HCC: Consistent Role of TACE
Liver Cancer (2025) https://doi.org/10.1159/000546697
Research Articles June 12 2025
Patient and Physician Preferences for Add-on Systemic Therapy to Transarterial Chemoembolization for Hepatocellular Carcinoma in Japan: A Discrete Choice Experiment
Liver Cancer (2025) https://doi.org/10.1159/000546693
Research Articles June 10 2025
Prognosis of hepatectomy versus systemic chemotherapy based on oncological resectability criteria for borderline resectable hepatocellular carcinoma
Liver Cancer (2025) https://doi.org/10.1159/000546830
Letters May 31 2025
Reply to the Letter Regarding “Combination Assay of Methylated HOXA1 with Tumor Markers for Detection of Early-Stage Hepatocellular Carcinoma”
Liver Cancer (2025) https://doi.org/10.1159/000546560
Editorials May 29 2025
Depth of Response Predicts Survival in Unresectable HCC Treated with Immunotherapy: Not All Stable Disease Is Equal
Liver Cancer (2025) https://doi.org/10.1159/000546698
Research Articles May 26 2025
Camrelizumab combined with Lenvatinib and RALOX-HAIC for unresectable hepatocellular carcinoma (Cal Era): a prospective, single-arm, phase II trial
Liver Cancer (2025) https://doi.org/10.1159/000546575
Research Articles May 26 2025
Etiology of hepatocellular carcinoma may influence the pattern of progression under atezolizumab-bevacizumab.
Liver Cancer (2025) https://doi.org/10.1159/000545494
Research Articles May 22 2025
Transarterial Chemoembolization plus Sorafenib versus Sorafenib Alone in Advanced Hepatocellular Carcinoma (SELECT): a Multicenter, Phase 3, Randomized, Controlled Trial
Liver Cancer (2025) https://doi.org/10.1159/000546530
Research Articles May 19 2025
The Risk of Decompensation in Steatotic Liver Disease Related Hepatocellular Carcinoma: A Comparison with Viral-controlled Cases
Liver Cancer (2025) https://doi.org/10.1159/000546492

or Create an Account

Close Modal
Close Modal